TMEM106B risk converges on C-terminal fragment homeostasis: genetics, mechanisms and therapy

Clicks: 12
ID: 333528
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #448 of 456 articles by views in Brain research

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 456 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract TMEM106B is a genetic modifier influencing susceptibility to multiple neurodegenerative disorders, including frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP), Alzheimer’s disease, Parkinson’s disease, and limbic-predominant age-related TDP-43 encephalopathy, as well as contributing to healthy brain aging and neuronal reserve. The gene harbours single nucleotide polymorphisms and structural variants that define risk and protective haplotypes, and despite extensive efforts to identify the functional variant within these haplotypes, consensus remains elusive. In this review, we synthesize current knowledge of TMEM106B genetics from human cohorts and mechanistic studies, highlighting how variants may influence its regulatory network and protein levels, with an emphasis on its aggregation-prone C-terminal domain. We further integrate evidence on the roles of TMEM106B within the endo-lysosomal system and beyond, including insights into protein structure, posttranslational modifications, interactors, proteolytic processing, and fibril formation. These findings are contextualized using data from mouse and induced pluripotent stem cell (iPSC) models, highlighting current gaps in the available models and the advances required to study its functions and cleavage. Finally, we explore therapeutic strategies targeting TMEM106B, focusing on modulation of expression, specific functional pathways, and fibril formation.
Reference Key
openalex_W7223242222 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Miranda Lastra Osua, Jolien Perneel, Cristina T. Vicente, Rosa Rademakers
Are you one of these authors? Claim your profile
Journal Brain research
Year 2026
DOI
10.1093/brain/awag367
URL
https://doi.org/10.1093/brain/awag367
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.